Altus Pharmaceuticals Inc. (ALTU) Chief Executive Officer, Sheldon Berkle to Ring The NASDAQ Stock Market Opening Bell

Company to Celebrate One Year Listing Anniversary on NASDAQ


ADVISORY, Feb. 6, 2007 (PRIME NEWSWIRE) --



 What:  
 Sheldon Berkle, Chief Executive Officer of Altus Pharmaceuticals Inc. 
 (ALTU) will preside over the opening bell to celebrate the Company's 
 One Year Listing Anniversary on NASDAQ.
  
 Where:
 NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

 When: 
 Wednesday, February 7, 2007 at 9:30 a.m. ET

 Contacts:
 John Jordan
 Senior Director, Corporate Communications
 Altus Pharmaceuticals, Inc. 
 617-299-2852 (office)
 617-899-8112 (cell)

 NASDAQ MarketSite:
 Jolene Libretto; 646.441.5220; mobile - 347.219.9539
 Jolene.Libretto@NASDAQ.com

Feed Information:

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.

Webcast:

A live Webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Altus Pharmaceuticals Inc. (ALTU):

Altus was created in 1993 to research and refine our proprietary protein crystallization and cross-linking technology. Crystallization and cross-linking of proteins provide significant improvements in stability and concentration of proteins which leads to the opportunity for oral and parenteral delivery of proteins.

Today, Altus is building a robust pipeline of products to treat a number of serious medical conditions associated with chronic gastrointestinal and metabolic disease areas. Our vision is to be the worldwide leader in the rapid and efficient development of valuable orally-delivered and injectable protein replacement products to meet unmet medical needs.